Dr Maria Fragiadaki
Senior Lecturer
Translational Medicine and Therapeutics, The William Harvey Research Institute
Queen Mary University of London
Queen Mary University of London
Research
Kidney, Kidney-on-a-Chip, polycystic kidney disease, ADPKD, renal toxicity, drug screening
Interests
My lab is intrestrd in developing a kidney-on-chip (KoC) model for drug testing using patient-derived cells from Autosomal Dominant Polycystic Kidney Disease (ADPKD). This approach could significantly advance our understanding of ADPKD and accelerate drug discovery for this genetic disorder. By using patient-derived cells, you can create a more accurate representation of the disease microenvironment, allowing for better prediction of drug efficacy and toxicity. This model could be particularly valuable for testing novel therapies and for identifying potential biomarkers for ADPKD progression and treatment response.Publications
2023
Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in CancerMullenger JL, Zeidler MP and Fragiadaki M
International Journal of Molecular Sciences, Mdpi vol. 24 (16)
16-08-2023
2022
JAG1-NOTCH4 mechanosensing drives atherosclerosisSouilhol C, Ayllon BT, Li X, Diagbouga MR, Zhou Z, Canham L, Roddie H, Pirri D, Chambers EV, Dunning MJ, Ariaans M, Li J, Fang Y, Jørgensen HF, Simons M, Krams R, Waltenberger J, Fragiadaki M, Ridger V, De Val S, Francis SE, Chico TJA, Serbanovic-Canic J and Evans PC
Science Advances, American Association For The Advancement of Science vol. 8 (35)
02-09-2022
Grants
Mechanisms driving Autosomal Dominant Polycystic Kidney Disease; The novel role of the RNA-binding protein ANKHD1Maria Fragiadaki
£566,085 MRC Medical Research Council
01-02-2023 - 28-11-2025